Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | THPO | P40225 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 3/20 | 0.54 |
| ▸ | MME | P08473 | 1/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.35 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 1/20 | 0.35 |
| ▸ | FNTB | P49356 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bucillamine SCHEMBL5060887 | 1.00 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Bucillamine SCHEMBL522713 | 1.00 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Bucillamine SCHEMBL121965 | 1.00 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Bucillamine SCHEMBL4632094 | 0.91 | MAPT (0.50) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Bucillamine SCHEMBL28086441 | 0.88 | PTGS1 (0.56) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL6661780 | 0.86 | KDM4E (0.61) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL6661779 | 0.86 | KDM4E (0.61) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL9324856 | 0.86 | KDM4E (0.61) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL929192 | 0.85 | ACE (0.51) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL929188 | 0.85 | ACE (0.51) | MAPTKDM4ETHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875268-B2 | The use of certain dimercaptoamides as reducing agents, 2-mercapto-N-(2-mercaptoethyl)acetamide, results in curling that is satisfactoryin terms of intensity and in terms of hold over time; less substantial degradation of the hair fiber compared with the reducing agents of the prior art; permanent waves | L'OREAL S.A. (FR) | 2011-01-25 | — | — | US | claimed |
| EP-1584615-B1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | OREAL (FR) | 2008-05-28 | — | — | EP | claimed |
| US-20060013784-A1 | Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith | L'OREAL S.A. (FR) | 2006-01-19 | — | — | US | claimed |
| EP-1584615-A1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | L'OREAL (FR) | 2005-10-12 | — | — | EP | claimed |
| US-20230181607-A1 | THIOSACCHARIDES FOR USE IN TREATING CORONAVIRUS INFECTION | The University of the Regents of California (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230181607-A1 | THIOSACCHARIDES FOR USE IN TREATING CORONAVIRUS INFECTION | The University of the Regents of California (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230172885-A1 | THIOL-CONTAINING COMPOUNDS FOR USE IN TREATING CORONAVIRUS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-06-08 | — | — | US | disclosed |
| US-20230172885-A1 | THIOL-CONTAINING COMPOUNDS FOR USE IN TREATING CORONAVIRUS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-06-08 | — | — | US | disclosed |
| WO-2021231421-A1 | THIOL-CONTAINING COMPOUNDS FOR USE IN TREATING CORONAVIRUS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021231397-A1 | THIOSACCHARIDES FOR USE IN TREATING CORONAVIRUS INFECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-18 | — | — | WO | disclosed |
| US-20210154161-A1 | MODIFIED-RELEASE BUCILLAMINE COMPOSITIONS, KITS, AND METHODS FOR TREATING CYSTINURIA, ARTHRITIS, GOUT, AND RELATED DISORDERS | ALTIBIO INC (US) | 2021-05-27 | — | — | US | disclosed |
| EP-3658130-A1 | MODIFIED-RELEASE BUCILLAMINE COMPOSITIONS, KITS, AND METHODS FOR TREATING CYSTINURIA, ARTHRITIS, GOUT, AND RELATED DISORDERS | Altibio, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| WO-2019023346-A1 | MODIFIED-RELEASE BUCILLAMINE COMPOSITIONS, KITS, AND METHODS FOR TREATING CYSTINURIA, ARTHRITIS, GOUT, AND RELATED DISORDERS | ALTIBIO, INC. (US) | 2019-01-31 | — | — | WO | disclosed |
| WO-2019023346-A1 | MODIFIED-RELEASE BUCILLAMINE COMPOSITIONS, KITS, AND METHODS FOR TREATING CYSTINURIA, ARTHRITIS, GOUT, AND RELATED DISORDERS | ALTIBIO, INC. (US) | 2019-01-31 | — | — | WO | disclosed |
| US-7875268-B2 | The use of certain dimercaptoamides as reducing agents, 2-mercapto-N-(2-mercaptoethyl)acetamide, results in curling that is satisfactoryin terms of intensity and in terms of hold over time; less substantial degradation of the hair fiber compared with the reducing agents of the prior art; permanent waves | L'OREAL S.A. (FR) | 2011-01-25 | — | — | US | disclosed |
| EP-1584615-B1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | OREAL (FR) | 2008-05-28 | — | — | EP | disclosed |
| US-20060013784-A1 | Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith | L'OREAL S.A. (FR) | 2006-01-19 | — | — | US | disclosed |
| EP-1584615-A1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | L'OREAL (FR) | 2005-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060013784-A1 | Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith | KRT18, CKAP4, S100A4 | MAPT 998/4885KDM4E 488/4885THRB 4302/4885 |
| US-20230172885-A1 | THIOL-CONTAINING COMPOUNDS FOR USE IN TREATING CORONAVIRUS | CTH, SARS1, CBS | MAPT 1085/4885KDM4E 3990/4885THRB 3581/4885 |
| US-20210154161-A1 | MODIFIED-RELEASE BUCILLAMINE COMPOSITIONS, KITS, AND METHODS FOR TREATING CYSTINURIA, ARTHRITIS, GOUT, AND RELATED DISORDERS | SLC7A11, CBS, SSB | MAPT 4256/4885KDM4E 4591/4885THRB 1122/4885 |
| US-20230181607-A1 | THIOSACCHARIDES FOR USE IN TREATING CORONAVIRUS INFECTION | TMPRSS4, ACE, ACE2 | MAPT 2951/4885KDM4E 4488/4885THRB 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.